Análisis coste-eficacia de los antihipertensivos en dosis fijas

García Ruiz, A. J; Divisón Garrote, JA; García-Agua Soler, N; Morata García de la Puerta, F; Montesinos Gálvez, AC; Ávila Lachica, L.
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. impr.) ; 39(2): 77-84, mar. 2013. tab
Artigo Espanhol | IBECS (Espanha) | ID: ibc-110308

Documentos relacionados

  1. [Evaluation of the pharmacoeconomic efficacy of prestance in the treatment of hypertensive patients on the basis of the results of the POTENTIAL program].
  2. Comparative advantages of new drugs: French Pharmacoeconomic Committee is not sufficiently demanding.
  3. A pharmacoeconomic analysis of the collection and preservation of samples in the biobank of the "Instituto Nacional de Cancerología" in Mexico City.
  4. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
  5. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
  6. A Comprehensive Prospective Study of the Costs Associated With Evaluation of ß-Lactam Allergy.
  7. [The aspects of pricing policy in Azerbaijan pharmaceutical sector].
  8. Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature.
  9. The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems.
  10. [Feasibility analysis of application of future contract in Chinese materia medica transaction].